Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion
Abstract Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treat...
Gespeichert in:
| Veröffentlicht in: | Leukemia research 2010-11, Vol.34 (11), p.1410-1416 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1416 |
|---|---|
| container_issue | 11 |
| container_start_page | 1410 |
| container_title | Leukemia research |
| container_volume | 34 |
| creator | Fenaux, Pierre Bowen, David Gattermann, Norbert Hellström-Lindberg, Eva Hofmann, Wolf-Karsten Pfeilstöcker, Michael Sanz, Guillermo Santini, Valeria |
| description | Abstract Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine. |
| doi_str_mv | 10.1016/j.leukres.2010.05.021 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_swepu</sourceid><recordid>TN_cdi_swepub_primary_oai_swepub_ki_se_550299</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>1_s2_0_S0145212610002808</els_id><sourcerecordid>860373063</sourcerecordid><originalsourceid>FETCH-LOGICAL-c586t-79d6a3f0773f83a8df0415605a8e46716b04dc11fe926efe396a83532b7fea193</originalsourceid><addsrcrecordid>eNqFkkFv1DAQhS0EokvhJ4B845RlbMd2wgFUVRSQKoEEXLG8zoR6NxsHOykNvx5Huy0SEurJ1uh7Mx6_R8hzBmsGTL3arjucdhHTmkOugVwDZw_IilVaFLIS8iFZAStlwRlXJ-RJSlsAkDWrH5MTDgrqUpcr8v1ztG70znZ0SkhDS-1v6_zoG98j9T298j-uMBbRpx3dz9iFZk5DZ1PW0DT3TQx7TK_pWU_xZsA40sH22NEw-N6H_il51Nou4bPjeUq-Xbz7ev6huPz0_uP52WXhZKXGQteNsqIFrUVbCVs1LZRMKpC2wlJppjZQNo6xFmuusEVRK5tXFHyjW7SsFqekOPRNv3CYNmaIfm_jbIL15lja5RsaKYHXC1__lx9iaP6KboWMM1EKJUTWvjxoM_hzwjSavU8Ouy4vHqZkKgVCC1D3k1rKEpjUkEl5IF0MKUVs717EwCx-m605-m0Wvw1Ik_3OuhfHCdNmj82d6tbgDLw9AJh__9pjNMl57B02PqIbTRP8vSPe_NPBddnbnJgdzpi2YYp9ttYwk7gB82UJ3ZI5luPGK6jEH2jv1Uc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>755401570</pqid></control><display><type>article</type><title>Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion</title><source>MEDLINE</source><source>SWEPUB Freely available online</source><source>Access via ScienceDirect (Elsevier)</source><creator>Fenaux, Pierre ; Bowen, David ; Gattermann, Norbert ; Hellström-Lindberg, Eva ; Hofmann, Wolf-Karsten ; Pfeilstöcker, Michael ; Sanz, Guillermo ; Santini, Valeria</creator><creatorcontrib>Fenaux, Pierre ; Bowen, David ; Gattermann, Norbert ; Hellström-Lindberg, Eva ; Hofmann, Wolf-Karsten ; Pfeilstöcker, Michael ; Sanz, Guillermo ; Santini, Valeria</creatorcontrib><description>Abstract Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.</description><identifier>ISSN: 0145-2126</identifier><identifier>ISSN: 1873-5835</identifier><identifier>EISSN: 1873-5835</identifier><identifier>DOI: 10.1016/j.leukres.2010.05.021</identifier><identifier>PMID: 20609474</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Antimetabolites, Antineoplastic ; Azacitidine ; Azacitidine - therapeutic use ; Drugs ; Hematology, Oncology and Palliative Medicine ; High-risk ; Humans ; Int-2 ; MDS ; Medicin och hälsovetenskap ; Myelodysplastic syndromes ; Myelodysplastic Syndromes - drug therapy ; Recommendations ; Risk</subject><ispartof>Leukemia research, 2010-11, Vol.34 (11), p.1410-1416</ispartof><rights>Elsevier Ltd</rights><rights>2010 Elsevier Ltd</rights><rights>Copyright © 2010 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c586t-79d6a3f0773f83a8df0415605a8e46716b04dc11fe926efe396a83532b7fea193</citedby><cites>FETCH-LOGICAL-c586t-79d6a3f0773f83a8df0415605a8e46716b04dc11fe926efe396a83532b7fea193</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.leukres.2010.05.021$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,314,552,780,784,885,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20609474$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:121343633$$DView record from Swedish Publication Index$$Hfree_for_read</backlink></links><search><creatorcontrib>Fenaux, Pierre</creatorcontrib><creatorcontrib>Bowen, David</creatorcontrib><creatorcontrib>Gattermann, Norbert</creatorcontrib><creatorcontrib>Hellström-Lindberg, Eva</creatorcontrib><creatorcontrib>Hofmann, Wolf-Karsten</creatorcontrib><creatorcontrib>Pfeilstöcker, Michael</creatorcontrib><creatorcontrib>Sanz, Guillermo</creatorcontrib><creatorcontrib>Santini, Valeria</creatorcontrib><title>Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion</title><title>Leukemia research</title><addtitle>Leuk Res</addtitle><description>Abstract Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.</description><subject>Antimetabolites, Antineoplastic</subject><subject>Azacitidine</subject><subject>Azacitidine - therapeutic use</subject><subject>Drugs</subject><subject>Hematology, Oncology and Palliative Medicine</subject><subject>High-risk</subject><subject>Humans</subject><subject>Int-2</subject><subject>MDS</subject><subject>Medicin och hälsovetenskap</subject><subject>Myelodysplastic syndromes</subject><subject>Myelodysplastic Syndromes - drug therapy</subject><subject>Recommendations</subject><subject>Risk</subject><issn>0145-2126</issn><issn>1873-5835</issn><issn>1873-5835</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>D8T</sourceid><recordid>eNqFkkFv1DAQhS0EokvhJ4B845RlbMd2wgFUVRSQKoEEXLG8zoR6NxsHOykNvx5Huy0SEurJ1uh7Mx6_R8hzBmsGTL3arjucdhHTmkOugVwDZw_IilVaFLIS8iFZAStlwRlXJ-RJSlsAkDWrH5MTDgrqUpcr8v1ztG70znZ0SkhDS-1v6_zoG98j9T298j-uMBbRpx3dz9iFZk5DZ1PW0DT3TQx7TK_pWU_xZsA40sH22NEw-N6H_il51Nou4bPjeUq-Xbz7ev6huPz0_uP52WXhZKXGQteNsqIFrUVbCVs1LZRMKpC2wlJppjZQNo6xFmuusEVRK5tXFHyjW7SsFqekOPRNv3CYNmaIfm_jbIL15lja5RsaKYHXC1__lx9iaP6KboWMM1EKJUTWvjxoM_hzwjSavU8Ouy4vHqZkKgVCC1D3k1rKEpjUkEl5IF0MKUVs717EwCx-m605-m0Wvw1Ik_3OuhfHCdNmj82d6tbgDLw9AJh__9pjNMl57B02PqIbTRP8vSPe_NPBddnbnJgdzpi2YYp9ttYwk7gB82UJ3ZI5luPGK6jEH2jv1Uc</recordid><startdate>20101101</startdate><enddate>20101101</enddate><creator>Fenaux, Pierre</creator><creator>Bowen, David</creator><creator>Gattermann, Norbert</creator><creator>Hellström-Lindberg, Eva</creator><creator>Hofmann, Wolf-Karsten</creator><creator>Pfeilstöcker, Michael</creator><creator>Sanz, Guillermo</creator><creator>Santini, Valeria</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>H94</scope><scope>ADTPV</scope><scope>AOWAS</scope><scope>D8T</scope><scope>ZZAVC</scope></search><sort><creationdate>20101101</creationdate><title>Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion</title><author>Fenaux, Pierre ; Bowen, David ; Gattermann, Norbert ; Hellström-Lindberg, Eva ; Hofmann, Wolf-Karsten ; Pfeilstöcker, Michael ; Sanz, Guillermo ; Santini, Valeria</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c586t-79d6a3f0773f83a8df0415605a8e46716b04dc11fe926efe396a83532b7fea193</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antimetabolites, Antineoplastic</topic><topic>Azacitidine</topic><topic>Azacitidine - therapeutic use</topic><topic>Drugs</topic><topic>Hematology, Oncology and Palliative Medicine</topic><topic>High-risk</topic><topic>Humans</topic><topic>Int-2</topic><topic>MDS</topic><topic>Medicin och hälsovetenskap</topic><topic>Myelodysplastic syndromes</topic><topic>Myelodysplastic Syndromes - drug therapy</topic><topic>Recommendations</topic><topic>Risk</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Fenaux, Pierre</creatorcontrib><creatorcontrib>Bowen, David</creatorcontrib><creatorcontrib>Gattermann, Norbert</creatorcontrib><creatorcontrib>Hellström-Lindberg, Eva</creatorcontrib><creatorcontrib>Hofmann, Wolf-Karsten</creatorcontrib><creatorcontrib>Pfeilstöcker, Michael</creatorcontrib><creatorcontrib>Sanz, Guillermo</creatorcontrib><creatorcontrib>Santini, Valeria</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SwePub</collection><collection>SwePub Articles</collection><collection>SWEPUB Freely available online</collection><collection>SwePub Articles full text</collection><jtitle>Leukemia research</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Fenaux, Pierre</au><au>Bowen, David</au><au>Gattermann, Norbert</au><au>Hellström-Lindberg, Eva</au><au>Hofmann, Wolf-Karsten</au><au>Pfeilstöcker, Michael</au><au>Sanz, Guillermo</au><au>Santini, Valeria</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion</atitle><jtitle>Leukemia research</jtitle><addtitle>Leuk Res</addtitle><date>2010-11-01</date><risdate>2010</risdate><volume>34</volume><issue>11</issue><spage>1410</spage><epage>1416</epage><pages>1410-1416</pages><issn>0145-2126</issn><issn>1873-5835</issn><eissn>1873-5835</eissn><abstract>Abstract Azacitidine is currently the only drug to have shown a significant survival benefit over conventional care regimens in patients with International Prognostic Scoring System (IPSS) intermediate-2 (Int-2) and high-risk myelodysplastic syndromes (MDS), establishing it as an important new treatment for these individuals. However, several aspects of the practical use of azacitidine remain uncertain. This manuscript outlines recommendations discussed by a panel of experts, providing a practical guide for physicians to ensure optimal management of Int-2 and high-risk patients receiving azacitidine.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>20609474</pmid><doi>10.1016/j.leukres.2010.05.021</doi><tpages>7</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0145-2126 |
| ispartof | Leukemia research, 2010-11, Vol.34 (11), p.1410-1416 |
| issn | 0145-2126 1873-5835 1873-5835 |
| language | eng |
| recordid | cdi_swepub_primary_oai_swepub_ki_se_550299 |
| source | MEDLINE; SWEPUB Freely available online; Access via ScienceDirect (Elsevier) |
| subjects | Antimetabolites, Antineoplastic Azacitidine Azacitidine - therapeutic use Drugs Hematology, Oncology and Palliative Medicine High-risk Humans Int-2 MDS Medicin och hälsovetenskap Myelodysplastic syndromes Myelodysplastic Syndromes - drug therapy Recommendations Risk |
| title | Practical use of azacitidine in higher-risk myelodysplastic syndromes: An expert panel opinion |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T17%3A36%3A49IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_swepu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Practical%20use%20of%20azacitidine%20in%20higher-risk%20myelodysplastic%20syndromes:%20An%20expert%20panel%20opinion&rft.jtitle=Leukemia%20research&rft.au=Fenaux,%20Pierre&rft.date=2010-11-01&rft.volume=34&rft.issue=11&rft.spage=1410&rft.epage=1416&rft.pages=1410-1416&rft.issn=0145-2126&rft.eissn=1873-5835&rft_id=info:doi/10.1016/j.leukres.2010.05.021&rft_dat=%3Cproquest_swepu%3E860373063%3C/proquest_swepu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=755401570&rft_id=info:pmid/20609474&rft_els_id=1_s2_0_S0145212610002808&rfr_iscdi=true |